Wetherby Asset Management Inc. increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 4.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,277 shares of the company’s stock after buying an additional 495 shares during the period. Wetherby Asset Management Inc.’s holdings in Zoetis were worth $766,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Assetmark Inc. raised its position in shares of Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock worth $102,000 after buying an additional 85 shares in the last quarter. Guardian Life Insurance Co. of America raised its position in shares of Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after buying an additional 13 shares in the last quarter. Point72 Asia Hong Kong Ltd acquired a new position in shares of Zoetis during the first quarter worth $111,000. Advisory Services Network LLC acquired a new position in shares of Zoetis during the first quarter worth $112,000. Finally, First Interstate Bank raised its position in shares of Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock worth $120,000 after buying an additional 76 shares in the last quarter. 94.51% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Inc. (NYSE:ZTS) opened at 59.74 on Friday. The company has a 50 day moving average price of $62.30 and a 200 day moving average price of $57.96. The stock has a market capitalization of $29.32 billion, a price-to-earnings ratio of 33.77 and a beta of 1.02. Zoetis Inc. has a 12 month low of $46.86 and a 12 month high of $63.85.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.53. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the business posted $0.49 EPS. Equities research analysts predict that Zoetis Inc. will post $2.34 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Wetherby Asset Management Inc. Buys 495 Shares of Zoetis Inc. (ZTS)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/wetherby-asset-management-inc-buys-495-shares-of-zoetis-inc-zts/1473709.html.

A number of research analysts have weighed in on the company. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $62.00 price target on shares of Zoetis in a research note on Monday. Cowen and Company set a $70.00 price target on Zoetis and gave the stock a “buy” rating in a research note on Monday, July 17th. Deutsche Bank AG lowered Zoetis from a “buy” rating to a “hold” rating and set a $65.00 price target on the stock. in a research note on Tuesday, July 25th. Jefferies Group LLC increased their price target on Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, May 9th. Finally, Cantor Fitzgerald assumed coverage on Zoetis in a research note on Friday, June 16th. They set an “overweight” rating and a $75.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the company. Zoetis has an average rating of “Buy” and a consensus target price of $64.78.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.